Proxceq™ is a one-of-a-kind, tissue-based tumor profiling solution designed to provide a deeper understanding of each patient’s cancer and support more personalized treatment strategies. By integrating multiple layers of molecular insight into a single analysis, it helps uncover key biological drivers, identify relevant therapeutic opportunities, and reveal pathways influencing treatment response. This holistic approach goes beyond conventional testing, enabling more informed clinical decisions and expanding the potential for tailored cancer care.
Simultaneous integration of genomic alterations, gene expression, and protein-level biomarkers
Expression analysis across 20,802 genes enables pathway-level insights not captured by standard panels
Eliminates the need for multiple sequential tests, reducing time and tissue requirements
Turning Complex Tumor Data into Meaningful Clinical Insight
Align therapy strategies with the unique biology of each tumor.
Capture a broader view of tumor mechanisms beyond surface-level alterations
Identify opportunities across targeted therapies, immunotherapies, and clinical trials
Receive consolidated, easy-to-interpret outputs for faster clinical action
Greater Depth. Wider Perspective. Clearer Answers.
Simultaneously evaluates multiple molecular dimensions for a more complete picture
Reveals pathway activity and tumor behavior through gene expression analysis
Improves identification of clinically relevant molecular events through integrated analysis
Delivers a cohesive report combining diverse biomarker insights into a single framework
From Initial Diagnosis to Advanced Disease
Highlights potential treatment approaches aligned with tumor biology
Identifies alternative mechanisms and pathways in refractory settings
Provides insights into why therapies may lose effectiveness over time
Supports evaluation of suitability for immunotherapy-based approaches
Facilitates matching to relevant investigational therapies
Comprehensive Molecular Assessment in a Single Test
Detection of SNVs, InDels, and copy number alterations (CNAs)
Identification of gene fusions and rearrangements
Whole transcriptome analysis enabling pathway-level insights
Assessment of overall mutational load to support immunotherapy decisions
Identification of DNA repair deficiencies relevant for targeted therapies
Evaluation of genomic instability markers
Protein-level assessment to guide immunotherapy selection
Included as applicable based on tumor type
Cancer is driven by complex and interconnected biological processes that cannot always be captured through a single layer of testing. Proxceq™ addresses this by combining multiple molecular dimensions, enabling a more complete understanding of tumor behavior. This integrated approach enhances the ability to identify actionable insights, uncover hidden therapeutic opportunities, and better stratify patients—particularly in complex or advanced disease settings.
Tumor tissue (FFPE or fresh biopsy) collected for analysis
High-quality extraction enabling multi-layered profiling
Simultaneous evaluation across multiple molecular dimensions
Advanced analytics translate findings into clinically relevant insights
Clear, prioritized outputs to guide personalized treatment decisions